Development Programs

Differentiated prodrug candidates initially targeting established IBD market with potential to address shortcomings of existing therapies

❯ More

PALI-2108 (PDE4 B/D Target)

Indication
Ulcerative Colitis (UC)

Status
Phase 1a/b

Highlights
Completed SAD, MAD, FE and first UC patient

Topline data on-track and expected H1 2025

IND and Ph1b/2a expected to commence in Q1 2026

Indication
Fibrostenotic Crohn’s Disease (FSCD)

Status
Phase 1a

Highlights
Leveraging Phase 1a data to accelerate development

PoC for fibrotic pathway engagement complete

IND and Ph1b/2a expected to commence in Q1 2026

PDE4 Platform

Precision Medicine Approach

Sign Up For Alerts